Crucell
AcquiredLeiden, Netherlands · Founded 2000 · $97.0M raised
- Headquarters
- Leiden
- Employees
- 201–500
- Founded
- 2000
- Business Model
- B2B
- Total Funding
- $97.0M
- Last Round
- $97.0M Venture RoundJan 2001
- Rounds
- 1
- Acquired by
- Johnson & JohnsonApr 2011 · $2.4B
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 6 investors for this company. The full record is or through the API.
About
Crucell was a global biopharmaceutical company headquartered in Leiden, Netherlands, dedicated to developing vaccines and antibody-based medicines for infectious diseases. Founded in 2000 through a merger of Dutch biotech companies IntroGene and U-BiSys, Crucell pioneered the AdVac and PER.C6 cell-line manufacturing platforms for producing next-generation vaccines including those targeting hepatitis B, malaria, and childhood diseases. The company was acquired by Johnson & Johnson in 2011 and subsequently folded into Janssen Vaccines.
Summary
Crucell is a Biotech company based in Leiden, Netherlands, founded in 2000. It has raised $97.0M in total across 1 round, most recently a $97.0M Venture Round in Jan 2001. Investors include Johnson & Johnson Innovation, Alta Partners and Atlas Venture.
Funding & Exit History
Apr 2011
Sign up to see all 2 events
Funding: Venture Round. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/crucell"><img src="https://indexed.vc/api/badge/company/crucell" alt="Crucell on Indexed.vc" width="260" height="76" /></a>